• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经疾病基因治疗的当前进展与挑战:临床医生综述

Current Advances and Challenges in Gene Therapies for Neurologic Disorders: A Review for the Clinician.

作者信息

Porcari Giulia Stefania, Collyer John Warren, Adang Laura Ann, Rajan Deepa Soundara

机构信息

Children's Hospital of Philadelphia, PA; and.

University of Pittsburgh, UPMC Children's Hospital of Pittsburgh, PA.

出版信息

Neurol Genet. 2025 Jan 13;11(1):e200229. doi: 10.1212/NXG.0000000000200229. eCollection 2025 Feb.

DOI:10.1212/NXG.0000000000200229
PMID:39810751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11731373/
Abstract

Over 300 million people globally are affected by rare diseases, many of which present predominantly with neurologic symptoms. Rare neurologic disorders pose significant diagnostic and therapeutic challenges including delayed diagnoses, limited treatment options, and a shortage of specialists. However, advancements in diagnostics, particularly next-generation sequencing and expansion of newborn screening, have significantly shortened the time to diagnosis for many of these disorders. Concurrently, the past decade has witnessed exponential development of new treatments for rare neurologic diseases, with several approved gene therapies and more trials under way. A range of targeted therapies now offers hope for not only symptomatic management but also for disease modification. As treatments transition from clinical trials to clinical practice, the responsibility of identifying and monitoring patients may increasingly fall on the general neurologists. This evolving therapeutic landscape highlights the urgent need to enhance our understanding of this new class of medications and the details on clinical eligibility and monitoring of patients with diseases that have approved gene therapies. This article provides a comprehensive overview of gene-targeted therapies currently available for neurologic disorders, with a focus on their mechanisms, challenges, and post-treatment considerations.

摘要

全球有超过3亿人受到罕见病的影响,其中许多主要表现为神经系统症状。罕见神经系统疾病带来了重大的诊断和治疗挑战,包括诊断延迟、治疗选择有限以及专家短缺。然而,诊断技术的进步,特别是下一代测序和新生儿筛查范围的扩大,显著缩短了许多此类疾病的诊断时间。与此同时,在过去十年中,罕见神经系统疾病的新疗法呈指数级发展,有几种基因疗法已获批准,还有更多试验正在进行。一系列靶向疗法现在不仅为症状管理带来了希望,也为疾病改善带来了希望。随着治疗从临床试验转向临床实践,识别和监测患者的责任可能越来越多地落在普通神经科医生身上。这种不断演变的治疗格局凸显了迫切需要加强我们对这类新药物的理解,以及对已批准基因疗法疾病患者的临床适用性和监测细节的了解。本文全面概述了目前可用于神经系统疾病的基因靶向疗法,重点介绍其作用机制、挑战以及治疗后注意事项。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb6/11731373/4e0676bf2fd9/NXG-2024-100280f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb6/11731373/4e0676bf2fd9/NXG-2024-100280f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb6/11731373/4e0676bf2fd9/NXG-2024-100280f1.jpg

相似文献

1
Current Advances and Challenges in Gene Therapies for Neurologic Disorders: A Review for the Clinician.神经疾病基因治疗的当前进展与挑战:临床医生综述
Neurol Genet. 2025 Jan 13;11(1):e200229. doi: 10.1212/NXG.0000000000200229. eCollection 2025 Feb.
2
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.《2018年炎症性肠病在加拿大的影响:患有炎症性肠病的儿童和青少年》
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Leukodystrophies.脑白质营养不良
Continuum (Minneap Minn). 2022 Aug 1;28(4):1194-1216. doi: 10.1212/CON.0000000000001130.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges.确保患者能够获得针对罕见病的基因疗法:应对报销和保险覆盖方面的挑战。
Mol Ther Methods Clin Dev. 2025 Jan 17;33(1):101403. doi: 10.1016/j.omtm.2024.101403. eCollection 2025 Mar 13.
7
Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts.成人神经障碍的基因检测:适应证、方法及临床影响。
J Neurol. 2024 Feb;271(2):733-747. doi: 10.1007/s00415-023-12058-6. Epub 2023 Oct 27.
8
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology.精准治疗发作性偏头痛:疾病生物学见解推动下靶向治疗的不断演变格局。
Expert Opin Biol Ther. 2025 Mar;25(3):229-243. doi: 10.1080/14712598.2025.2456464. Epub 2025 Feb 2.
9
Current genetic diagnostics in inborn errors of immunity.当前免疫缺陷病的基因诊断
Front Pediatr. 2024 Apr 10;12:1279112. doi: 10.3389/fped.2024.1279112. eCollection 2024.
10
Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.推进治疗前沿:用于治疗回肠和肛周克罗恩病的新型药物研发进程
Therap Adv Gastroenterol. 2024 Dec 19;17:17562848241303651. doi: 10.1177/17562848241303651. eCollection 2024.

引用本文的文献

1
Ten Years of ® : Reflecting on the Past, Inspiring the Future.十年的®:回顾过去,激励未来。
Neurol Genet. 2025 Jan 31;11(1):e200252. doi: 10.1212/NXG.0000000000200252. eCollection 2025 Feb.

本文引用的文献

1
Therapeutic targeting of RNA for neurological and neuromuscular disease.RNA 靶向治疗在神经和神经肌肉疾病中的应用。
Genes Dev. 2024 Sep 19;38(15-16):698-717. doi: 10.1101/gad.351612.124.
2
Secondary failure of lentiviral vector gene therapy in a cerebral adrenoleukodystrophy patient with an ABCD1 whole-gene deletion.ABCD1 全基因缺失的脑肾上腺脑白质营养不良患者慢病毒载体基因治疗的继发性失败。
Mol Ther. 2024 Oct 2;32(10):3313-3317. doi: 10.1016/j.ymthe.2024.08.005. Epub 2024 Aug 5.
3
Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).
《2024年全球新生儿血斑筛查现状:2020 - 2023年近期活动综合回顾》
Int J Neonatal Screen. 2024 May 23;10(2):38. doi: 10.3390/ijns10020038.
4
Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States.美国异染性脑白质营养不良监测与管理的共识指南
Cytotherapy. 2024 Jul;26(7):739-748. doi: 10.1016/j.jcyt.2024.03.487. Epub 2024 Apr 1.
5
Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System.用于脊髓性肌萎缩症罕见病的孤儿药onasemnogene abeparvovec(Zolgensma)的真实世界安全性数据:一项基于欧洲药品管理局不良事件报告系统的药物警戒研究。
Pharmaceuticals (Basel). 2024 Mar 19;17(3):394. doi: 10.3390/ph17030394.
6
Evidence review and considerations for use of first line genome sequencing to diagnose rare genetic disorders.一线基因组测序用于诊断罕见遗传疾病的证据综述及考量因素
NPJ Genom Med. 2024 Feb 26;9(1):15. doi: 10.1038/s41525-024-00396-x.
7
Surface modification of lipid nanoparticles for gene therapy.脂质纳米粒的基因治疗表面修饰。
J Gene Med. 2024 Jan;26(1):e3642. doi: 10.1002/jgm.3642. Epub 2023 Dec 3.
8
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.依洛硫酸酯酶纳治疗遗传性转甲状腺素蛋白淀粉样变性多发性神经病。
JAMA. 2023 Oct 17;330(15):1448-1458. doi: 10.1001/jama.2023.18688.
9
Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification.脊髓性肌萎缩症的联合疾病修正治疗:一种分类建议。
Ann Clin Transl Neurol. 2023 Nov;10(11):2155-2160. doi: 10.1002/acn3.51889. Epub 2023 Sep 10.
10
A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel.一项针对儿童进行性脑白质营养不良历史和当前治疗选择的临床疗效和安全性的系统评价,包括 atidarsagene autotemcel。
Orphanet J Rare Dis. 2023 Aug 29;18(1):248. doi: 10.1186/s13023-023-02814-2.